Form 8-K - Current report:
SEC Accession No. 0001213900-24-087267
Filing Date
2024-10-11
Accepted
2024-10-11 16:15:34
Documents
14
Period of Report
2024-10-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0217430-8k_cero.htm   iXBRL 8-K 36712
  Complete submission text file 0001213900-24-087267.txt   264437

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cero-20241009.xsd EX-101.SCH 3798
3 XBRL DEFINITION FILE cero-20241009_def.xml EX-101.DEF 27115
4 XBRL LABEL FILE cero-20241009_lab.xml EX-101.LAB 37493
5 XBRL PRESENTATION FILE cero-20241009_pre.xml EX-101.PRE 25736
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0217430-8k_cero_htm.xml XML 6108
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241367730
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)